GIA632
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 14, 2026
VITESS: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
(clinicaltrials.gov)
- P2 | N=210 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Vitiligo
February 18, 2026
CGIA632A12201: Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis
(clinicaltrialsregister.eu)
- P1/2 | N=52 | Recruiting | Sponsor: Novartis Pharma AG
New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
February 25, 2026
VITESS: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
(clinicaltrials.gov)
- P2 | N=210 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • Dermatology • Immunology • Vitiligo
November 15, 2025
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=84 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 4
Of
4
Go to page
1